A computational study of CYP3A4 mediated drug interaction profiles for anti-HIV drugs

Journal of Molecular Modeling

Volumn 17, Issue 8, 2011, Pages 1847-1854

  Mannu, Jayakanthan ^a   Jenardhanan, Pranitha ^a   Mathur, Premendu P ^a  

^a PONDICHERRY UNIVERSITY   (India)

Author keywords

Binding conformation; CYP3A4; Docking; Drug drug interaction; Entry inhibitor; NNRTI

Indexed keywords

ANTIRETROVIRUS AGENT; CYTOCHROME P450 3A4; DELAVIRDINE; EFAVIRENZ; ETRAVIRINE; MARAVIROC; PROTEINASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; DRUG BINDING; DRUG CONFORMATION; DRUG METABOLISM; DRUG STRUCTURE; ENZYME ACTIVE SITE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS; MOLECULAR DOCKING; NONHUMAN; PRIORITY JOURNAL;

ANTI-HIV AGENTS; BINDING SITES; CATALYTIC DOMAIN; CYTOCHROME P-450 CYP3A; DRUG DESIGN; DRUG INTERACTIONS; HUMANS; MODELS, MOLECULAR; MOLECULAR CONFORMATION;

EID: 80051796318     PISSN: 16102940     EISSN: 09485023     Source Type: Journal    
DOI: 10.1007/s00894-010-0890-6     Document Type: Article

References (36)

1. JA Sterne MA Hernan B Ledergerber K Tilling R Weber P Sendi M Rickenbach JM Robins M Egger 2005 Long-term effectiveness of potent antiretroviral therapy in preventing aids and death: a prospective cohort study Lancet 366 378 384 10.1016/S0140-6736(05)67022-5 10.1016/S0140-6736(05)67022-5 1:CAS:528: DC%2BD2MXmvVWmsbc%3D (Pubitemid 41073955)
2. SJ Gange Y Barron RM Greenblatt K Anastos H Minkoff M Young A Kovacs M Cohen WA Meyer 3rd A Munoz 2002 Effectiveness of highly active antiretroviral therapy among hiv-1 infected women J Epidemiol Commun Health 56 153 159 10.1136/jech.56.2.153 10.1136/jech.56.2.153 1:STN:280:DC%2BD38%2FptlOnsg%3D%3D (Pubitemid 34098470)
3. SA Sheweita 2000 Drug-metabolizing enzymes: mechanisms and functions Curr Drug Metab 1 107 132 10.2174/1389200003339117 10.2174/1389200003339117 1:CAS:528:DC%2BD3cXntlOrs78%3D
4. KC Brown S Paul ADM Kashuba 2009 Drug interactions with new and investigational antiretrovirals Clin Pharmacokinet 48 211 241 10.2165/00003088-200948040-00001 10.2165/00003088-200948040-00001 1:CAS:528:DC%2BD1MXptVeiurs%3D
5. E Tanaka 1998 Clinically important pharmacokinetic drug-drug interactions: role of cytochrome p450 enzymes J Clin Pharm Ther 23 403 416 10.1046/j.1365-2710.1998.00086x 10.1046/j.1365-2710.1998.00086.x 1:CAS:528:DyaK1MXhsVGjsbg%3D (Pubitemid 29060690)
6. B Kjellander CM Masimirembwa I Zamora 2007 Exploration of enzyme-ligand interactions in cyp2d6 and 3a4 homology models and crystal structures using a novel computational approach J Chem Inf Model 47 1234 1247 10.1021/ci600561v 10.1021/ci600561v 1:CAS:528:DC%2BD2sXjtlCmtrw%3D (Pubitemid 46973737)
7. A Oda N Yamaotsu S Hirono 2004 Studies of binding modes of (s)-mephenytoin to wild types and mutants of cytochrome P450 2 C19 and 2 C9 using homology modeling and computational docking Pharm Res 21 2270 2278 10.1007/s11095-004-7680-8 10.1007/s11095-004-7680-8 1:CAS:528: DC%2BD2MXjslyjtA%3D%3D (Pubitemid 40568441)
8. Y Ito H Kondo PS Goldfarb DF Lewis 2008 Analysis of cyp2d6 substrate interactions by computational methods J Mol Graph Model 26 947 956 10.1016/j.jmgm.2007.07.004 10.1016/j.jmgm.2007.07.004 1:CAS:528: DC%2BD2sXhsVOksL7F (Pubitemid 350298014)
9. Y Yao WW Han YH Zhou ZS Li Q Li XY Chen DF Zhong 2009 The metabolism of cyp2c9 and cyp2c19 for gliclazide by homology modeling and docking study Eur J Med Chem 44 854 861 10.1016/j.ejmech.2008.04.015 10.1016/j.ejmech.2008.04.015 1:CAS:528:DC%2BD1MXitlWjtb0%3D
10. M Jayakanthan S Chandrasekar J Muthukumaran PP Mathur 2010 Analysis of cyp3a4-hiv-1 protease drugs interactions by computational methods for highly active antiretroviral therapy in hiv/aids J Mol Graph Model 28 455 463 10.1016/j.jmgm.2009.10.005 10.1016/j.jmgm.2009.10.005 1:CAS:528: DC%2BD1MXhsFymsLnK
11. Berman H, Henrick K, Nakamura H, Markley JL (2007) The worldwide protein data bank (wwpdb): ensuring a single, uniform archive of pdb data. Nucleic Acids Res 35:D301-303. doi: 10.1093/nar/gkl971 (Pubitemid 46056219)
12. JK Yano MR Wester GA Schoch KJ Griffin CD Stout EF Johnson 2004 The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-Å resolution J Biol Chem 279 38091 38094 10.1074/jbc.C400293200 10.1074/jbc.C400293200 1:CAS:528:DC%2BD2cXnt1Oqs7c%3D (Pubitemid 39295952)
13. GM Morris DS Goodsell RS Halliday R Huey WE Hart RK Belew AJ Olson 1998 Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function J Comput Chem 19 1639 1662 10.1002/(SICI)1096- 987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B 10.1002/(SICI)1096- 987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B 1:CAS:528: DyaK1cXntFemur4%3D (Pubitemid 128590223)
14. EE Scott JR Halpert 2005 Structures of cytochrome p450 3a4 Trends Biochem Sci 30 5 7 10.1016/j.tibs.2004.11.004 10.1016/j.tibs.2004.11.004 1:CAS:528:DC%2BD2MXkslOksA%3D%3D (Pubitemid 40093733)
15. PA Williams J Cosme DM Vinkovic A Ward HC Angove PJ Day C Vonrhein IJ Tickle H Jhoti 2004 Crystal structures of human cytochrome p450 3a4 bound to metyrapone and progesterone Science 305 683 686 10.1126/science.1099736 10.1126/science.1099736 1:CAS:528:DC%2BD2cXmtFWqsrY%3D (Pubitemid 39006760)
16. Y Kapelyukh MJ Paine JD Marechal MJI Sutcliffe CR Wolf GCK Roberts 2008 Multiple substrate binding by cytochrome p450 3a4: estimation of the number of bound substrate molecules Drug Metab Dispos 36 2136 2144 10.1124/dmd.108.021733 10.1124/dmd.108.021733 1:CAS:528:DC%2BD1cXhtF2jtb7M
17. KR Korzekwa N Krishnamachary M Shou A Ogai RA Parise AE Rettie FJ Gonzalez TS Tracy 1998 Evaluation of atypical cytochrome p450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome p450 active sites Biochemistry 37 4137 4147 10.1021/bi9715627 10.1021/bi9715627 1:CAS:528:DyaK1cXhsVOltbw%3D (Pubitemid 28166435)
18. M Shou J Grogan JA Mancewicz KW Krausz FJ Gonzalez HV Gelboin KR Korzekwa 1994 Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome p450 active site Biochemistry 33 6450 6455 10.1021/bi00187a009 10.1021/bi00187a009 1:CAS:528:DyaK2cXkslOisLo%3D (Pubitemid 24189354)
19. MA Gibbs NA Hosea 2003 Factors affecting the clinical development of cytochrome p450 3a substrates Clin Pharmacokinet 42 969 984 10.2165/00003088- 200342110-00003 1:CAS:528:DC%2BD3sXnslGms78%3D (Pubitemid 37056104)
20. SM Fowler JM Taylor T Friedberg CR Wolf RJ Riley 2002 CYP3A4 active site volume modification by mutagenesis of leucine 211 Drug Metab Dispos 30 452 456 10.1124/dmd.30.4.452 10.1124/dmd.30.4.452 1:CAS:528:DC%2BD38Xis1OlsLc%3D (Pubitemid 34263831)
21. SM Fowler RJ Riley MP Pritchard MJ Sutcliffe T Friedberg CR Wolf 2000 Amino acid 305 determines catalytic center accessibility in CYP3A4 Biochemistry 39 4406 4414 10.1021/bi992372u 10.1021/bi992372u 1:CAS:528:DC%2BD3cXhvVyktrc%3D (Pubitemid 30212657)
22. F Roussel KK Khan JR Halpert 2000 The importance of SRS-1 residues in catalytic specificity of human cytochrome P450 3A4 Arch Biochem Biophys 374 269 278 10.1006/abbi.1999.1599 10.1006/abbi.1999.1599 1:CAS:528: DC%2BD3cXpsVagsg%3D%3D (Pubitemid 30120262)
23. JQ Tran JG Gerber BM Kerr 2001 Delavirdine: clinical pharmacokinetics and drug interactions Clin Pharmacokinet 40 207 226 10.1006/abbi.1999.1599 10.2165/00003088-200140030-00005 1:CAS:528:DC%2BD3MXjsVWmtrY%3D (Pubitemid 32324451)
24. M Harris C Alexander M O'Shaughnessy JSG Montaner 2002 Delavirdine increases drug exposure of ritonavir-boosted protease inhibitors AIDS 16 798 799 10.1097/00002030-200203290-00019 (Pubitemid 34274474)
25. LJ Scott CM Perry 2000 Delavirdine: a review of its use in HIV infection Drugs 60 1411 1444 10.2165/00003495-200060060-00013 1:CAS:528: DC%2BD3MXktFarug%3D%3D (Pubitemid 32039394)
26. D Gilden 1996 Delavirdine/protease inhibitor interactions GMHC Treat Issues 10 11 12 1:STN:280:DC%2BD3M3otVCntQ%3D%3D
27. BM Best M Goicoechea 2008 Efavirenz - still first-line king? Expert Opin Drug Metab Toxicol 4 965 972 10.1517/17425255.4.7.965 10.1517/17425255.4.7.965 1:CAS:528:DC%2BD1cXos1Chtbs%3D
28. E Dailly C Allavena F Raffi P Jolliet 2005 Pharmacokinetic evidence for the induction of lopinavir metabolism by efavirenz Br J Clin Pharmacol 60 32 34 10.1111/j.1365-2125.2005.02369.x 10.1111/j.1365-2125.2005.02369.x 1:CAS:528:DC%2BD2MXmvF2ktr8%3D (Pubitemid 40942778)
29. M Pfister L Labbe JF Lu SM Hammer J Mellors KK Bennett S Rosenkranz LB Sheiner 2002 Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir Clin Pharmacol Ther 72 133 141 10.1067/mcp.2002.126183 10.1067/mcp.2002.126183 1:CAS:528:DC%2BD38Xnt1aqt7k%3D (Pubitemid 35034491)
30. PA Pham CW Hendrix P Barditch-Crovo T Parsons W Khan M Parish C Radebaugh KA Carson GE Pakes R Qaqish C Flexner 2007 Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz Antivir Ther 12 963 969 1:CAS:528:DC%2BD2sXht1Ggu77F (Pubitemid 47492566)
31. E Martinez M Nelson 2010 Simplification of antiretroviral therapy with etravirine AIDS Rev 12 52 59
32. A Tseng RD MacArthur 2010 Profile of etravirine for the treatment of hiv infection Ther Clin Risk Manag 6 49 58 10.2147/TCRM.S3128 1:CAS:528: DC%2BC3cXhs1Cjtbg%3D
33. VE Perez C Sanchez-Parra SS Villar 2009 Etravirine drug interactions Enferm Infecc Microbiol Clín 27 Suppl 2 27 31 10.1016/S0213-005X(09) 73216-1 10.1016/S0213-005X(09)73216-1
34. G Peytavin 2008 clinical pharmacokinetic of maraviroc Méd Mal Infect 38 Suppl 1 S12 S16 10.1016/S0399-077X(08)70539-0 10.1016/S0399-077X(08) 70539-0 (Pubitemid 351711577)
35. S Abel TM Jenkins LA Whitlock CE Ridgway GJ Muirhead 2008 Effects of cyp3a4 inducers with and without cyp3a4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers Br J Clin Pharmacol 65 Suppl 1 38 46 10.1111/j.1365-2125.2008.03134.x 10.1111/j.1365-2125.2008.03134.x 1:CAS:528:DC%2BD1cXlt1Cgt74%3D (Pubitemid 351366537)
36. S Abel D Russell RJ Taylor-Worth CE Ridgway GJ Muirhead 2008 Effects of cyp3a4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers Br J Clin Pharmacol 65 Suppl 1 27 37 10.1111/j.1365-2125.2008.03133.x 10.1111/j.1365-2125.2008.03133.x 1:CAS:528:DC%2BD1cXlt1Cgtrk%3D (Pubitemid 351366536)